BeOne Medicines (ONC) Revenue (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Revenue data on file, last reported at $1.5 billion in Q1 2026.

• Quarterly Revenue rose 35.46% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 37.44% YoY) and the FY2025 annual result came in at $5.3 billion, up 40.23% from the prior year.
• Revenue rose to $1.5 billion in Q1 2026 per ONC's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Revenue topped out at $1.5 billion in Q1 2026 and bottomed at $306.6 million in Q1 2022.
• The 5-year median for Revenue is $781.3 million (2023), against an average of $855.4 million.
• Peak annual rise in Revenue reached 127.73% in 2022, while the deepest fall reached 49.39% in 2022.
• Tracing ONC's Revenue over 5 years: stood at $380.1 million in 2022, then surged by 66.91% to $634.4 million in 2023, then surged by 77.78% to $1.1 billion in 2024, then jumped by 32.84% to $1.5 billion in 2025, then gained by 1.02% to $1.5 billion in 2026.
• Per Business Quant, the three latest ONC Revenue figures stand at $1.5 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025).

Peer Comparison